South Africa Oral Antidiabetic Drug Market Size (2024 - 2029)

The South Africa Oral Anti-Diabetic Drug Market is projected to experience growth over the forecast period, driven by the increasing prevalence of diabetes and the impact of the COVID-19 pandemic on diabetes management. The pandemic has highlighted the challenges faced by diabetes patients, particularly those with poor glycemic control, leading to a greater demand for diabetic medications. This market expansion is further supported by advancements in diabetes care products and insulin-delivery devices, as manufacturers focus on innovative solutions to capture a larger market share.

Home Market Analysis Healthcare Research Device Drug Combination Research South Africa Oral Antidiabetic Drug Market Market Size

Market Size of South Africa Oral Antidiabetic Drug Industry

South Africa Oral Antidiabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 241.78 Million
Market Size (2029) USD 275.36 Million
CAGR (2024 - 2029) 2.00 %

Major Players

South Africa Oral Antidiabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

South Africa Oral Antidiabetic Drug Market Analysis

The South Africa Oral Antidiabetic Drug Market size is estimated at USD 241.78 million in 2024, and is expected to reach USD 275.36 million by 2029, growing at a CAGR of greater than 2% during the forecast period (2024-2029).

The COVID-19 pandemic favorably affected South Africa's market growth for diabetes medications. Diabetes problems, aberrant glucose variability, and increased blood glucose levels may be experienced by COVID-19-infected patients who have diabetes. In patients with either Type 1 (T1DM) or Type 2 diabetes mellitus (T2DM), the prevalence of diabetes significantly increased the severity and mortality of COVID-19, particularly about poor glycemic control. While, newly diagnosed diabetes (T1DM and T2DM) and newly diagnosed hyperglycemia have become more widely recognized in the context of COVID-19 and have been linked to poorer outcomes. 

A patient's blood glucose should be checked frequently to prevent aggravation. Pharmaceuticals known as diabetic medications were created to stabilize and regulate blood glucose levels in people with diabetes. Diabetes is frequently treated using diabetic medications. Diabetes patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications.

Numerous health issues are related to diabetes. Diabetes patients must make several daily adjustments to keep their blood glucose levels within acceptable ranges. For example, they may need extra insulin or consume more carbs. One of the main causes of illness, early mortality, and lost economic growth, diabetes is a growing healthcare burden for the nation. Obesity, a poor diet, and lack of exercise are the primary causes of the rise in newly diagnosed Type 1 and Type 2 diabetes cases. 

Diabetes care products are increasingly being used, as evidenced by the fast-rising incidence, prevalence, and healthcare costs in industrialized nations. Additionally, the market is expanding due to the increased prevalence of diabetes and the deployment of insulin-delivery devices. Leading manufacturers are concentrating on technical advancements and creating cutting-edge items to capture a sizeable portion of the market.

South Africa Oral Antidiabetic Drug Industry Segmentation

Oral antihyperglycemic agents lower glucose levels in the blood. They are commonly used in the treatment of diabetes mellitus. The South Afric oral anti-diabetic drug market is set to witness a cagr of more than 2% during the forecast period. The South Africa oral anti-diabetic drug market is segmented into drugs. The report offers the market size in value terms in USD and Volume in terms of Units for all the abovementioned segments.

Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Need A Different Region Or Segment?
Customize Now

South Africa Oral Antidiabetic Drug Market Size Summary

The South Africa oral anti-diabetic drug market is experiencing a steady expansion, driven by the increasing prevalence of diabetes and the growing demand for effective diabetes management solutions. The market is characterized by a significant focus on oral anti-diabetic medications, which are preferred due to their ease of use, cost-effectiveness, and higher patient adherence compared to insulin therapies. The rise in diabetes cases, particularly Type 2 diabetes, is attributed to lifestyle factors such as obesity, poor diet, and sedentary behavior. This has led to a heightened need for diabetes care products and medications to manage blood glucose levels effectively. The market is further bolstered by technological advancements and the introduction of innovative diabetes care devices, which are gaining traction among consumers.

The South African government and various organizations are actively working to combat the diabetes epidemic through preventive measures and public health initiatives. The implementation of a sugar tax and the Diabetes Prevention Programme (DPP) are key strategies aimed at reducing obesity and promoting healthier lifestyle choices. Additionally, organizations like Diabetes South Africa and the Society for Endocrinology, Metabolism, and Diabetes of South Africa are advocating for better diabetes care, increased public awareness, and improved access to medications. These efforts, combined with the market's focus on innovation and the presence of major pharmaceutical companies, are expected to enhance the market's growth prospects in the coming years.

Explore More

South Africa Oral Antidiabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

South Africa Oral Antidiabetic Drug Market Size FAQs

The South Africa Oral Antidiabetic Drug Market size is expected to reach USD 241.78 million in 2024 and grow at a CAGR of greater than 2% to reach USD 275.36 million by 2029.

In 2024, the South Africa Oral Antidiabetic Drug Market size is expected to reach USD 241.78 million.

South Africa Oral Antidiabetic Drug Market Report Snapshots

South Africa Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)